Here are a few analogies for Nuvation Bio (NUVB):

• Like a startup version of Bristol Myers Squibb's oncology drug development arm.
• An independent biotech company focused on discovering and developing novel cancer therapies, similar to an early-stage Amgen solely dedicated to oncology.

• Taletrectinib: A novel tyrosine kinase inhibitor for the treatment of ROS1-positive non-small cell lung cancer, currently in a registrational Phase 2 clinical trial.
• NUV-868: A potentially best-in-class PARP1-selective inhibitor in Phase 1 development for advanced solid tumors.

Nuvation Bio (NUVB) is a clinical-stage biopharmaceutical company focused on the development of oncology therapeutics.

As a clinical-stage company, Nuvation Bio has not yet commercialized any products. According to their latest available SEC filings (e.g., the 2023 Annual Report on Form 10-K), Nuvation Bio has **not generated any revenue from the sale of products or from collaboration agreements to date.**

Therefore, Nuvation Bio currently does not have major customers in the traditional sense, as they are still in the research and development phase and have not yet brought any products to market or entered into revenue-generating commercial partnerships.

• Piramal Pharma Ltd. (NSE: PIRAMALPHARM, BSE: 543678)
• Catalent, Inc. (CTLT)
• Lonza Group AG (LONN)

David Hung, M.D., Founder, President and Chief Executive Officer

Dr. Hung founded Nuvation Bio in 2018. Prior to that, he founded Medivation, Inc., in 2003, serving as its President and Chief Executive Officer. He oversaw Medivation's growth, including raising $433 million in public offerings, before the company was sold to Pfizer for $14.3 billion in an all-cash deal in 2016, marking one of the largest biopharma sales by a founding CEO.

Philippe Sauvage, Chief Financial Officer

Mr. Sauvage joined Nuvation Bio in 2024, bringing over 20 years of experience in building strategically aligned operations and finance teams in worldwide commercial settings. He most recently served as Global Head of Operations and Access at Sanofi. Previously, Mr. Sauvage was the Chief Financial Officer for Sanofi-Genzyme and Sanofi North America.

Colleen Sjogren, Chief Commercial Officer

Ms. Sjogren joined Nuvation Bio in 2024 and has nearly 30 years of experience in developing innovative, high-performing commercial organizations for successful product launches, including many leading oncology medicines. She most recently served as the Senior Vice President of U.S. Sales at Madrigal Pharmaceuticals.

Kerry Wentworth, Chief Regulatory Officer

Ms. Wentworth joined Nuvation Bio in 2022 with over 25 years of experience in both domestic and international Regulatory and Quality Affairs. Her background spans early and late development across multiple therapeutic areas including oncology, osteoarthritis, pain management, autoimmune, and rare diseases.

David Hanley, Ph.D., Chief Technical Operations Officer

Dr. Hanley joined Nuvation Bio in 2021, bringing 20 years of pharmaceutical industry experience in driving strategy for technical operations and chemistry manufacturing and controls (CMC), including virtual networks, for drug development, manufacturing, and distribution globally. His expertise includes diverse disease areas such as oncology, central nervous system (CNS), and autoimmune, as well as various product types.

The key risks to Nuvation Bio (NUVB) are primarily centered around its financial stability, the commercial success of its lead product, and the inherent uncertainties of its drug development pipeline.

1. High Cash Burn and Dependence on Single Product Revenue: Nuvation Bio operates as a high-burn, single-product-revenue biotechnology company. Its financial health is highly dependent on the commercial execution of IBTROZI (taletrectinib) and managing a multi-year gap before other pipeline assets can significantly contribute to revenue. The company reported a substantial net loss of $55.8 million in the third quarter of 2025, with negative operating cash flow highlighted as a key risk. Despite a strong cash position, the company is burning through its reserves to fund its pipeline and the commercial launch of IBTROZI.
2. Commercialization Challenges and Intense Competition for IBTROZI: The success of Nuvation Bio is largely tied to the successful commercialization of its recently approved drug, IBTROZI, for ROS1-positive non-small cell lung cancer (NSCLC). However, IBTROZI faces significant competition in a relatively small patient population from established treatments like Pfizer's Xalkori and emerging rivals, such as Nuvalent's zidesamtinib. The risk includes a slower-than-expected rollout of IBTROZI, or the emergence of new, more effective or better-tolerated therapies.
3. Clinical Trial Setbacks and Regulatory Hurdles for Pipeline Assets: The company's long-term growth and diversification depend on the successful advancement of its broader oncology pipeline, including candidates like safusidenib and NUV-1511. Any setbacks in ongoing clinical trials, such as unexpected severe adverse side effects, or failures to meet clinical endpoints, would pose a significant risk. Furthermore, the valuation of Nuvation Bio is dependent on achieving high-probability milestones for these unproven pipeline assets, underscoring the inherent regulatory risks and uncertainties in drug development.

Taletrectinib (IBTROZI™) for ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

• The estimated addressable market for IBTROZI™ in the United States is approximately $1 billion in the first year of commercial rollout, potentially growing to $3.8 billion by year four. This projection is based on an estimated 3,000 new ROS1-positive NSCLC patients annually in the U.S. and an annual treatment cost of around $350,000 per patient, factoring in the "stacking" of surviving patients.

• Nuvation Bio believes the market potential for ROS1-positive lung cancer in the U.S. is substantially larger than the current annual net sales of first-generation ROS1 TKIs, which are under $150 million and are considered underutilized.

• Globally, ROS1-positive disease is estimated to affect approximately 2% of the over one million people diagnosed with NSCLC each year.

Safusidenib for IDH1-mutant Glioma

null

NUV-1511 (Drug-Drug Conjugate) for Advanced Solid Tumors

null

NUV-868 (BD2-selective BET inhibitor) for Advanced Solid Tumors

null

Nuvation Bio (NUVB) is expected to drive future revenue growth over the next 2-3 years through the following key initiatives:

1. Continued Growth and Market Penetration of IBTROZI (taletrectinib) in ROS1-positive NSCLC in the U.S.: Following its FDA approval in June 2025, IBTROZI, a next-generation ROS1 inhibitor for advanced non-small cell lung cancer, has demonstrated strong early commercial success. The company reported significant net product revenue from IBTROZI in Q2 and Q3 2025, surpassing analyst expectations. Nuvation Bio has observed robust patient uptake, with 204 new patients starting treatment in Q3 2025, and broad payer coverage expanding to over 80% of covered lives. The company anticipates continuous patient growth for IBTROZI and targets a potential annualized net revenue of $55 million based on current patient starts. Updated clinical data showing unprecedented durability and a median duration of response of 50 months for TKI-naïve patients are expected to support a supplemental New Drug Application (sNDA) for a label update, further solidifying its market position.
2. International Commercial Expansion of IBTROZI: Nuvation Bio is actively pursuing and executing global commercialization strategies for IBTROZI. Regulatory approval in Japan was secured in September 2025 through a partnership with Nippon Kayaku, with a $25 million milestone payment expected upon the establishment of the reimbursement price by year-end 2025. Additionally, taletrectinib is anticipated to be listed on China's National Reimbursement Drug List in 2026. The company is also in late-stage discussions with potential commercialization partners in Europe and other ex-U.S. territories to further expand IBTROZI's reach and revenue streams.
3. Advancement and Potential Commercialization of Pipeline Assets: Beyond IBTROZI, Nuvation Bio's diversified oncology pipeline represents a significant driver of future revenue growth. Key among these is safusidenib, a brain-penetrant IDH1 inhibitor, which has advanced into a global, randomized Phase 3 trial (G203) for the maintenance treatment of high-grade IDH1-mutant astrocytoma. Successful clinical development and eventual regulatory approval of safusidenib could open up new revenue streams in a distinct oncology indication. The pipeline also includes NUV-1511, an innovative drug-drug conjugate (DDC) in a Phase 1/2 study, and NUV-868, a BD2-selective BET inhibitor. Continued progress and strategic development of these assets will bolster the company's long-term revenue potential and investor confidence.

Capital Allocation Decisions (Last 3-5 Years)

Share Issuance

• Nuvation Bio became a publicly traded company on February 11, 2021, through a business combination with Panacea Acquisition Corp..
• The company's shares outstanding increased significantly, rising by 53.9% in 2024 to 0.33 billion shares and by 1.13% in 2025 to 0.34 billion shares.
• In April 2024, Nuvation Bio issued approximately 113 million shares of common stock as part of the acquisition of AnHeart Therapeutics.

Inbound Investments

• Following its business combination in February 2021, Nuvation Bio reported a strong cash position of approximately $830 million after transaction fees.
• In March 2025, Nuvation Bio secured up to $250 million in non-dilutive financings from Sagard Healthcare Partners, which includes $150 million in royalty interest financing and $50 million in debt upon U.S. FDA approval of taletrectinib, with an option for an additional $50 million in debt.
• As of September 30, 2025, the company maintained a strong balance sheet with cash, cash equivalents, and marketable securities totaling $549.0 million.

Outbound Investments

• Nuvation Bio acquired AnHeart Therapeutics in April 2024 through a transaction valued at approximately $260 million, primarily involving the issuance of about 113 million shares of common stock.

Capital Expenditures

• Nuvation Bio's capital expenditures were relatively low over the past few years, with reported figures of $0.16 million in 2020, $0.06 million in 2021, $0.36 million in 2022, $0.28 million in 2023, and $0.15 million in 2024.
• Capital expenditures in the last 12 months were reported at approximately -$252,000.